Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies (PASSAGE)
About this Trial
Phase IV: a long term prospective multinational parallel-cohort study monitoring safety in patients with MS newly started on Fingolimod once daily or treated with another approved disease modifing therapy.
- Status: Enrolling now
- Location: Miami Valley Hospital South
- Principal Investigator: Tracy Eicher, MD
For more information about this study, visit ClinicalTrials.gov: NCT01442194
Contact Us
If you would like information about participating in this study, contact:
Don McHone, RN, BSN
(937) 208-4451
djmchone@premierhealth.com
Last edited on 01/11/2019.
